Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease

Lignende værker

• Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
  af: Patoulias, Dimitrios, et al.
  Udgivet: (2020)
• Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
  af: Patoulias, Dimitrios Ioannis
  Udgivet: (2019)
• Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease
  af: Huang, Xiao-Dong, et al.
  Udgivet: (2008)
• Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
  af: Dimitrios Patoulias, et al.
  Udgivet: (2018-12-01)
• Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
  af: Patoulias, Dimitrios, et al.
  Udgivet: (2018)